thrombocyte function after elective CABG with CPB

Thrombocyte function after elective coronary artery bypass graft operation with cardiopulmonary bypass.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27232

Enrollment

Registered

2013-10-08

Start date

2013-10-14

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

platelet function (platjes functie), cardiac surgery (hart chirurgie), platelet function recovery (platejs funtcie herstel)

Interventions

The use of cardiopulmonary bypass during elective coronary artery bypass operations.

Eligibility

Inclusion criteria

Inclusion criteria: elective patients scheduled for CABG more than 250.00 thrombocyte/mcl

Exclusion criteria

Exclusion criteria: low thrombocyte count (below 250.000/mcl) use of platelet inhibitors other tha aspirine known thrombocytes dysfunction

Design outcomes

Primary

Measure	Time frame
Multiple impedance electrode aggregometry (MEA- Multiplate multiple impedance aggregometry Dynabyte Medical, Munich, Germany), Light transmission aggregometry (LTA-platelet aggregometer PAR-4, Hart Biologicals Ltd., Hartlepool UK)	—

Secondary

Measure	Time frame
Clinical parameters of bleeding (blood loss and transfusion requirements within the first 24 hours postoperative).	—

Contacts

Public ContactM.D. Lancé

dept of anesthesiology MUMC+ P.Debeyelaan 25

marcus.lance@mumc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)